FDA stresses dangers of transplant meds

The FDA is warning doctors again that organ-transplant drugs CellCept (from Roche) and Myfortic (Novartis) have been linked to miscarriages and birth defects when taken by pregnant women. Last October, the agency announced that it had received reports of these side effects, and at the time added warnings to the two drugs' labels. The new round of FDA alerts doesn't stem from additional reports of safety problems, but from the agency's fear that physicians didn't get the initial heads-up. Before prescribing the drugs, the agency says, doctors should confirm that their transplant patients are not pregnant, and should make sure that the patients are using effective contraception.

Patient who'd experienced miscarriages and birth defects were mostly mothers who took CellCept before their pregnancies were detected. Some were taking the med not because they'd received organ transplants, but to treat rheumatoid arthritis and lupus--both off-label uses for the drug.

The new warning comes just a month after another CellCept alert: FDA announced in April that it was investigating 16 patients who'd developed a rare neurological disease while taking it.

- check out the FDA alert
- see the Associated Press story

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.